Dainippon Sumitomo Prepares 2011 Schizophrenia Drug Launch In The U.S.
This article was originally published in PharmAsia News
Executive SummaryMajor Japanese drug maker Dainippon Sumitomo will establish a holding company in the U.S. in July to prepare for an NDA submission to U.S. FDA for novel schizophrenia drug lurasidone (SM-13496). The company plans to submit the NDA for the antipsychotic agent with FDA in the first half of 2010, said President Masayo Tata, June 15. According to Dainippon Sumitomo, late-stage clinical trials for lurasidone resulted in promising results in confirming the drug's efficacy and safety, which prompted the company to move up the planned launch date in the U.S. from 2012 to 2011. (Click here for more - Japanese Language
You may also be interested in...
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.